Gilead Sciences Beheer
Beheer criteriumcontroles 2/4
De CEO Gilead Sciences is Dan O'Day, benoemd in Mar2019, heeft een ambtstermijn van 7.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 28.44M, bestaande uit 6.3% salaris en 93.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.049% van de aandelen van het bedrijf, ter waarde $ 82.46M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.2 jaar en 6.5 jaar.
Belangrijke informatie
Dan O'Day
Algemeen directeur
US$28.4m
Totale compensatie
| Percentage CEO-salaris | 6.31% |
| Dienstverband CEO | 7.3yrs |
| Eigendom CEO | 0.05% |
| Management gemiddelde ambtstermijn | 6.2yrs |
| Gemiddelde ambtstermijn bestuur | 6.5yrs |
Recente managementupdates
Recent updates
Seeking Alpha • Jun 23
Gilead Sciences: The Market Is Underestimating Its Growth Runway
Summary Gilead Sciences offers a compelling long-term value opportunity after a significant pullback, with a "Buy" rating reaffirmed. GILD's core HIV franchise drives 72% of sales, with robust growth from Biktarvy and rapid adoption of Yeztugo, now expected to reach $1 billion in annual sales. Management raised 2026 revenue growth guidance to 5.5% at midpoint, citing strong HIV performance and momentum in oncology with Trodelvy. GILD maintains a strong A- rated balance sheet, low leverage, and a well-covered 2.65% dividend, supporting future strategic flexibility. Read the full article on Seeking Alpha
Narratiefupdate • Jun 12
GILD: Diversified Oncology And HIV Pipeline Will Support Future Earnings
Analyst price targets for Gilead Sciences have been refined to $180.00, with updated assumptions reflecting slightly lower revenue growth, a modestly higher profit margin, a small reduction in the discount rate, and a marginally lower future P/E, as analysts balance enthusiasm for assets like Trodelvy, Yeztugo, lenacapavir, and the Tubulis platform against more cautious long term expectations. Analyst Commentary Recent Street research shows a mix of enthusiasm and caution around Gilead, with bullish analysts highlighting specific growth drivers and valuation support while others keep a more measured stance on key oncology and I&I assets.
Narratiefupdate • May 28
GILD: HIV And Oncology Pipeline Expansion Will Drive Long Term Upside
Gilead Sciences' updated analyst price target edges up to $157.83 from $157.43, with analysts pointing to slightly higher modeled revenue growth, a modestly higher assumed future P/E of about 22.4x, and the growing contribution they see from assets like Trodelvy, Yeztugo and the Tubulis platform, even as views on long term oncology and I&I potential remain restrained. Analyst Commentary Analysts are split between those leaning into Gilead's newer growth drivers and those keeping a closer eye on execution risks and valuation.
Nieuw narratief • May 19
Attractive medium-term compounder with catalyst-rich profile, but with short-term volatility tied to investment phase
Below is a professional investment memo (buy‑side style, in English) on Gilead Sciences (GILD) based primarily on the 2025 Impact Report (pipeline + strategy + data extraction) and complemented with verified investor website + latest news analysis. Investment Memo – Gilead Sciences (NASDAQ: GILD) 1.
Narratiefupdate • May 01
GILD: Future Returns Will Hinge On Executing Oncology And ADC Acquisitions
Analysts have raised the Gilead Sciences fair value estimate by about $2 to $128.42 per share, supported by refreshed models that reflect updated revenue growth, profitability, and future P/E assumptions following a wave of higher Street price targets. Analyst Commentary Street research on Gilead has tilted constructive in recent weeks, with several firms lifting price targets and at least one new Buy rating added.Narratiefupdate • Apr 17
GILD: Oncology Deals And HIV Franchise Will Support Future Earnings
Analysts have raised the price target for Gilead Sciences to $180, citing recent upward revisions across Wall Street that reflect updated views on revenue growth, profitability and oncology deal activity. The core fair value estimate in this framework also remains at $180.Narratiefupdate • Apr 03
GILD: HIV And PrEP Franchise Will Support Future Earnings And Margin Strength
Analysts have lifted the fair value estimate for Gilead Sciences to $180 from $159, citing higher modeled revenue growth, a slightly lower discount rate, and support from a wave of recent price target raises and positive initiation commentary on the company’s positioning and operating margins. Analyst Commentary Street research around Gilead Sciences has been active, with several bullish analysts updating their views and price targets in recent weeks.Narratiefupdate • Mar 20
GILD: HIV Franchise And Oncology Expansion Will Shape Bullish Long Term Outlook
The analyst fair value estimate for Gilead Sciences has moved from $132.57 to $157.43, with analysts pointing to stronger modeled revenue growth, slightly higher long term profit margins, and a higher future P/E multiple supported by recent price target hikes and positive views on the company's positioning in large cap biotech. Analyst Commentary Recent Street research on Gilead Sciences reflects a mix of optimism around growth drivers and caution around valuation and competitive risks.Narratiefupdate • Mar 05
GILD: Rich HIV Outlook Will Depend On Delivering High-Risk Oncology Acquisitions
Analysts have lifted their Gilead Sciences fair value estimate from $122.64 to $126.09 as they update models to reflect revised revenue growth and profit margin assumptions, along with a slightly higher discount rate and a modestly lower future P/E multiple, following a wave of higher Street price targets in recent weeks. Analyst Commentary Recent Street research around Gilead Sciences shows a mix of optimism and restraint.Narratiefupdate • Feb 19
GILD: Elevated Future Expectations Will Hinge On Execution In Oncology
Gilead Sciences' updated analyst price target has moved sharply higher to $122.64 from $91.83, as analysts broadly lift their targets into the $140 to $170 range, citing steadier HIV franchise expectations, contributions from recent launches, and adjusted assumptions for expenses and oncology assets. Analyst Commentary Recent Street research shows a clear tilt toward higher valuation frameworks for Gilead Sciences, with several firms taking their targets into a broad US$140 to US$170 range.Narratiefupdate • Feb 05
GILD: Extended HIV And PrEP Strength Will Support Steady Long-Term Earnings Power
Narrative Update: Gilead Sciences Analyst Price Target Shift Analysts have lifted their price targets on Gilead Sciences by as much as US$20, pointing to updated HIV franchise expectations, revised oncology and PrEP assumptions, and refreshed valuation approaches, even as some models incorporate higher IPR&D expenses and adjusted sales forecasts. Analyst Commentary Recent Street research around Gilead centers on two big themes in the models: the durability of the HIV franchise and the ramp in newer areas like PrEP and oncology, with several bullish analysts lifting price targets and reaffirming positive ratings.Narratiefupdate • Jan 22
GILD: Extended HIV Franchise Strength Will Support Stronger Long-Term Earnings Power
Analysts have nudged their fair value estimate for Gilead Sciences up to $159 from $153, citing refreshed models that reflect updated HIV franchise expectations, oncology pipeline inputs, and evolving competitive readthroughs from peers in hepatitis and cell therapy. Analyst Commentary Recent Street research around Gilead Sciences has leaned constructive, with several bullish analysts refining their models and resetting price targets while pointing to HIV, oncology, and select liver and autoimmune assets as the key drivers they are watching.Narratiefupdate • Jan 07
GILD: HIV PrEP Strength And Oncology Mixed Results Will Shape Outlook
Analysts have nudged their price targets on Gilead Sciences higher, generally toward the US$140 to US$145 range. They cite expectations for stronger HIV PrEP contributions from Yeztugo, a healthier outlook for the broader HIV portfolio including Biktarvy, and ongoing support from oncology and newer launches such as Livdelzi.Narratiefupdate • Dec 20
GILD: Extended HIV Exclusivity Will Support Stronger Long-Term Earnings Power
Analysts have raised their fair value estimate for Gilead Sciences to $153 from $140, citing extended Biktarvy exclusivity, a stronger long term HIV growth outlook supported by Yeztugo and PrEP, and increasing conviction in oncology and broader large cap biopharma innovation potential. Analyst Commentary Bullish analysts continue to highlight Gilead as a core large cap biopharma holding, pointing to a healthier long term growth profile in HIV and a strengthening contribution from oncology.Narratiefupdate • Dec 06
GILD: Extended HIV Franchise Will Offset Oncology And Policy Uncertainty Ahead
Analysts have nudged their blended price target for Gilead Sciences slightly lower by about $0.20 to the low-$130s, reflecting modestly higher discount rates and more conservative HIV and oncology growth and margin assumptions, even as they highlight extended Biktarvy exclusivity, encouraging Yeztugo uptake, and anito cel driven oncology optionality as key long term value drivers. Analyst Commentary Bullish analysts largely frame the recent price target tweaks as fine tuning within an increasingly constructive long term view, pointing to extended HIV cash flows, a strengthening PrEP opportunity, and optionality in oncology despite early stage competitive readouts.Narratiefupdate • Nov 22
GILD: Extended Exclusivity And PrEP Opportunities Will Balance Ongoing Oncology And Policy Pressures
Analysts have modestly raised their price target for Gilead Sciences to $130.83 per share from $129.51. They cite the extended exclusivity period for Biktarvy and improved growth prospects in the HIV market as key drivers for the upward revision.Narratiefupdate • Nov 08
GILD: HIV Business Strength And Patent Extension Will Balance Oncology Risks Ahead
Gilead Sciences' price target has been raised by analysts from $127 to $145. This reflects confidence in stable HIV business trends and improved execution, which offsets ongoing oncology and cell therapy challenges.Narratiefupdate • Oct 25
Patent Extension And Policy Decisions Will Drive Access To Advanced Therapies
Gilead Sciences' analyst price target has increased from $126 to $127 per share. Analysts point to continued strong uptake of the Yeztugo launch in HIV and the recent Biktarvy patent extension as supporting factors, despite some pipeline setbacks.Narratiefupdate • Oct 10
Global Healthcare Trends Will Expand Access To Advanced Therapies
Gilead Sciences saw its analyst price target increase from $124.91 to $126.31. Analysts cited improved sales forecasts for key HIV treatments and enhanced revenue growth expectations as the primary drivers of the upward revision.Narratiefupdate • Sep 04
Global Healthcare Trends Will Expand Access To Advanced Therapies
Analysts remain constructive on Gilead Sciences, citing strong HIV franchise performance, positive FDA developments, and favorable regulatory tailwinds offsetting minor pipeline setbacks, resulting in an unchanged consensus price target of $124.37. Analyst Commentary Yeztugo’s FDA approval and clean label, strong clinical data, and convenient twice-yearly dosing are seen as key drivers for Gilead’s HIV franchise growth, with analysts generally positive on long-term adoption despite initial ramp expectations being slow and some cannibalization of Descovy anticipated.Analyseartikel • Jul 27
Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$9b |
| Dec 31 2025 | US$28m | US$2m | US$9b |
| Sep 30 2025 | n/a | n/a | US$8b |
| Jun 30 2025 | n/a | n/a | US$6b |
| Mar 31 2025 | n/a | n/a | US$6b |
| Dec 31 2024 | US$24m | US$2m | US$480m |
| Sep 30 2024 | n/a | n/a | US$126m |
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$485m |
| Dec 31 2023 | US$23m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$5b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$22m | US$2m | US$5b |
| Sep 30 2022 | n/a | n/a | US$3b |
| Jun 30 2022 | n/a | n/a | US$4b |
| Mar 31 2022 | n/a | n/a | US$5b |
| Dec 31 2021 | US$19m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$5b |
| Mar 31 2021 | n/a | n/a | US$301m |
| Dec 31 2020 | US$19m | US$2m | US$123m |
| Sep 30 2020 | n/a | n/a | US$1b |
| Jun 30 2020 | n/a | n/a | -US$257m |
| Mar 31 2020 | n/a | n/a | US$5b |
| Dec 31 2019 | US$29m | US$1m | US$5b |
Compensatie versus markt: De totale vergoeding ($USD 28.44M ) Dan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 14.71M ).
Compensatie versus inkomsten: De vergoeding van Dan is het afgelopen jaar met meer dan 20% gestegen.
CEO
Dan O'Day (61 yo)
7.3yrs
Tenure
US$28,437,198
Compensatie
Mr. Daniel Patrick O'Day, also known as Dan, served as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019 until March 26, 2024. He served as Member of Supervisory Board at Galap...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 7.3yrs | US$28.44m | 0.049% $ 82.5m | |
| Executive VP & CFO | 6.7yrs | US$8.77m | 0.014% $ 23.3m | |
| Chief Commercial & Corporate Affairs Officer | 7yrs | US$9.30m | 0.010% $ 16.9m | |
| Chief Medical Officer | 1.5yrs | US$13.92m | 0.0015% $ 2.6m | |
| Senior VP | less than a year | geen gegevens | geen gegevens | |
| Senior Vice President of Treasury & Investor Relations | 5.5yrs | geen gegevens | geen gegevens | |
| Executive VP | less than a year | geen gegevens | 0.00043% $ 725.1k | |
| Executive Vice President of Human Resources | 6.9yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Research | 6.4yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Research | 5.3yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Intercontinental Region & Global Patient Solutions | 6.2yrs | geen gegevens | geen gegevens | |
| VP of Oncology & Franchise Head of Early Development | no data | geen gegevens | geen gegevens |
6.2yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van GILD is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & CEO | 7.3yrs | US$28.44m | 0.049% $ 82.5m | |
| Lead Independent Director | 5.8yrs | US$479.96k | 0.0010% $ 1.8m | |
| Independent Director | 2.4yrs | US$409.92k | 0.00044% $ 742.0k | |
| Independent Director | 8.5yrs | US$429.92k | 0.0022% $ 3.7m | |
| Independent Director | 8.2yrs | US$432.44k | 0.0012% $ 2.0m | |
| Independent Director | 5.6yrs | US$409.78k | 0.00081% $ 1.4m | |
| Independent Director | 9.9yrs | US$437.44k | 0.00011% $ 185.5k | |
| Independent Director | 6.1yrs | US$409.92k | 0.0011% $ 1.8m | |
| Independent Director | 6.5yrs | US$433.94k | 0.00051% $ 860.0k |
6.5yrs
Gemiddelde duur
71yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van GILD wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.5 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/09 04:05 |
| Aandelenkoers aan het einde van de dag | 2026/07/09 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Gilead Sciences, Inc. wordt gevolgd door 64 analisten. 24 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| James Birchenough | Barclays |